Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 4,290,000 shares, a decline of 6.3% from the March 31st total of 4,580,000 shares. Based on an average daily volume of 403,100 shares, the […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 4,290,000 shares, a decrease of 6.3% from the March 31st total of 4,580,000 shares. Based on an average trading volume of 403,100 shares, the days-to-cover ratio is […]
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) have been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have updated their coverage on the stock […]
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) shot up 5.2% on Monday . The stock traded as high as $20.81 and last traded at $20.56. 223,320 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 399,462 shares. The stock had previously closed at $19.54. Analyst Upgrades […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Dana Pizzuti sold 8,212 shares of the stock in a transaction that occurred on Wednesday, April 5th. The stock was sold at an average price of $16.15, for a total value of $132,623.80. Following the completion of the transaction, the insider now directly owns 4,500 shares in […]